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Background: The risk of cancer with hypercalcaemia in primary care is unknown.
Methods: This was a cohort study using calcium results in patients aged X40 years in a primary care electronic data set.
Diagnoses of cancer in the following year were identified.
Results: Participants (54 267) had calcium results: 1674 (3%) were X2.6mmol l 1. Hypercalcaemia was strongly associated with
cancer, especially in males: OR 2.92, 95% CI 2.17–3.93, P¼o0.001; positive predictive value (PPV) 11.5%; females: OR 1.86, 95% CI
1.39–2.50, Po0.001: PPV 4.1%.
Conclusions: Hypercalcaemia is strongly associated with cancer in primary care, with men at most risk, despite hypercalcaemia
being more common in women.
Hypercalcaemia has many causes, the most common being
primary hyperparathyroidism and cancer, although nearly all
studies originate from secondary care (Fisken et al, 1980; Greaves
et al, 1992). In one such secondary care study, 100 out of 145
Japanese patients with corrected calcium 42.7mmol l 1 had a
malignant cause identified (Tokuda et al, 2007). In an earlier UK
study at a tertiary centre, 219 of 496 patients with hypercalcaemia
had cancer: however, all but four had already been diagnosed with
cancer (Fisken et al, 1980). Other UK secondary care studies report
cancer in 29–44% (Harrop et al, 1982; Rajathurai and Cove-Smith,
1984). In contrast, a small Swedish primary care study, using a
2.55mmol l 1 threshold, found only 4 out of 142 patients to have
cancer, and 99 patients did not receive a diagnosis (Dalemo et al,
2006). To our knowledge, there have been no UK primary care
studies, so we aimed to calculate the prospective risk of cancer in
hypercalcaemic patients without a prior diagnosis of malignancy.
MATERIALS AND METHODS
This was a retrospective cohort study of UK primary care patients
in the General Practice Research Database (GPRD)—now the
Clinical Practice Research Datalink. These data include all
diagnoses and laboratory investigations from primary care.
Participants. Participants in this study were a control group from
a previous study (DISCOVERY), and were patients aged X40
years who were age- and sex-matched controls to case patients with
one of 13 common cancers. Controls were excluded if they had the
same cancer as their case, but they could have any other cancer.
These control patients are described as ‘participants’ henceforth.
We studied all participants with a calcium result between January
2000 and June 2009, defining those 42.6mmol l 1 on any
occasion as hypercalcaemic, with their first elevated calcium level
as the index date. In normocalcaemic participants, the date of their
first calcium test was assigned as their index date. The sole
exclusion criterion for all participants was a past or current
diagnosis of non-skin cancer. Non-skin cancers were identified in
the year after the index date and categorised the by cancer site.
Analysis. The main analytical method was logistic regression.
Secondary analyses categorised hypercalcaemia into: 2.6–2.79,
2.8–2.99, andX3mmol l 1, and estimated positive predictive values
(PPVs) for cancer in the next year directly. Stata 12 (Statacorp,
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College Station, TX, USA) was used for all analyses. A power
calculation, using a 4% difference in cancer outcomes between
hypercalcaemic and normocalcaemic participants (80% power, 5%
alpha) suggested a sample size of 5085 would be required, although
many more were available.
RESULTS
Participants (54 267) had a calcium value during the study. Their
demographics, summary calcium values and cancer outcomes are
shown in Table 1. Table 2 shows the multivariable analysis
separated by the genders, as the associations between hypercalcaemia
and cancer were strikingly different. The PPVs (95% binomial
confidence intervals) for cancer in men were 11.5% (11.1–11.9) for
calciums between 2.60–2.79mmol l 1, 27.9% (27.3–28.4) for
2.8–2.99mmol l 1 and 50.0% (49.4–50.6) for 43.0mmol l 1.
In women, the corresponding PPVs were 4.1% (3.9–4.4), 8.7%
(8.3–9.0) and 16.7% (16.2–17.1). In men, the most prevalent
cancers were lung (18 cases, 34% of total), prostate (11, 21%),
myeloma, colorectal, and other haematological cancers (4 each, 8%).
Twelve other cancers were identified (19%). In women, the most
prevalent were myeloma (12, 24%), breast (9, 18%), other
haematological cancers (5, 10%), lung (4, 8%), and metastatic cancer
with unknown primary (4, 8%). There were 16 other cancers (32%).
There was no difference between the calcium levels in the different
cancers (Kruskal–Wallis test: P¼ 0.38 for men, 0.52 for women).
DISCUSSION
This paper appears to be the first large primary care study to
quantify the risk of cancer in patients with hypercalcaemia.
Previous associations with malignancy were confirmed with a
striking difference in the risk of cancer between the genders,
and a strong relationship between calcium levels and risk.
The fact that our study was based on data from a primary
care setting is important, as our results can guide primary care
practitioners in investigation of hypercalcaemia; secondary care
studies—with their much higher prevalence of cancer—cannot
do so.
Strengths and weaknesses of the study. This study was large,
giving ample power for the primary outcome. However, the data
set does not exactly represent a standard primary care population,
being derived from a population matched by age and sex to a
cancer population. The incidence of cancer in this study is likely to
be higher than in an all-age general population, but equally so for
hypercalcaemic and normocalcaemic participants. Hence, the odds
ratios in the multivariable analyses should be correct, but the PPVs
may be slight overestimates. The study relied on accurate recording
of cancer outcomes by GPs, but studies confirm that coding in the
GPRD is generally accurate, especially in cancer (Khan et al, 2010;
Dregan et al, 2012). However, it is likely some cancers were
omitted, for example, a patient dying in hospital from cancer, but
the cancer never being added to the primary care records.
Assuming this sequence of events is more common in hypercal-
caemic patients, this bias will have slightly reduced the PPVs.
We chose a single threshold of 2.6mmol l 1 to define
hypercalcaemia. Although this simplified the study, it did not
accommodate variation in local laboratory assay methods and
normal ranges. Furthermore, we used corrected calcium, adjusted
for albumin. This was deliberate as it is the figure most commonly
used by GPs. Use of the first raised calcium value ignored any
repeat measurements, the results of which could illuminate the
clinical situation. Again, this was deliberate.
The alternative of using the highest value would have been of
less clinical utility—as the clinician is never in the position of
knowing that the result they have actually is the highest value. The
final limitation is that we do not know why the GP performed a
calcium analysis. As there are multiple reasons for GPs to perform
tests, one of which is to look for cancer, the results cannot be
extrapolated to the asymptomatic population. It is likely that our
participants were more likely to have cancer than the general
population, although our comparison group also had calcium
testing.
It would have been useful to include other causes for
hypercalcaemia, such as endocrine disease, in this analysis, but
unfortunately our analysis indicated poor GPRD coding for non-
cancer diagnoses, as these were often made in secondary care.
Comparison with previous literature. No primary care studies on
hypercalcaemia have focussed specifically on cancer, but some have
examined hypercalcaemia in the community. In a Swedish
community study of hypercalcaemia, 6 out of 127 (5%) patients
had an early diagnosis of cancer (Dalemo et al, 2006). However, it
was not reported whether or not the blood test preceded the cancer
diagnosis or what the exact follow-up for each patient was, so it is
impossible to estimate an annual incidence. By 10 years of follow-
up, 15 (12%) hypercalcaemic patients had developed cancer. These
figures are hard to compare with ours as our follow-up was shorter
(to try and avoid unrelated cancers being identified), although are
broadly in agreement. As in our study, three-quarters of
hypercalcaemic patients were female, but the risk of cancer with
hypercalcaemia was higher in males.
Implications for clinical practice. This study should help GPs
investigate hypercalcaemia appropriately. Although there have
been many reports on the causes and prognosis of hypercalcaemia
in secondary care, there is little evidence from primary care.
Table 1. Demographic and clinical details of participants
Hypercalcaemic
participants
Normocalcaemic
participants
Number of patients 1674 52593
Age, years (median, IQR) 74.6 (68–82) 71.3 (63–80)
Male (%) 27.5% (460) 46.3% (24 362)
Calcium (median, IQR) 2.70 (2.63–2.72) 2.32 (2.25–2.39)
Calcium if cancer
diagnosed (median, IQR)
2.80 (2.64–2.83) 2.33 (2.26–2.41)
Cancer within 1 year (n, %) 103 (6.2%) 1571 (3.0%)
Table 2. Multivariable analysis of putative explanatory variables for
cancer in both genders
Variable
Males (n¼24822)
Odds ratio (95% CI)
Females (n¼29445)
Odds ratio (95% CI)
Age (per year) 1.04 (1.04–1.05) 1.02 (1.02–1.03)
Hypercalcaemia 2.92 (2.17–3.93) 1.86 (1.39–2.50)
Cancer associations by calcium range
Calcium
2.6–2.79mmol l1
2.18 (1.54–3.10) 1.61 (1.15–2.24)
Calcium
2.8 up to 3.0mmol l1
6.18 (2.93–13.0) 2.60 (1.05–6.44)
Calcium43.0mmol l1 27.7 (10.12–75.7) 8.67 (3.58–21.0)
Note: All the associations shown in Table 2 P-valueso0.001.
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The risk of malignancy correlated with the degree of
hypercalcaemia, with significant differences between men and
women (OR 2.14, Po0.001). In men, even mild hypercalcaemia
(2.6–2.8mmol l 1) conferred a risk of cancer in 1 year of 11.5%. If
the calcium was above 2.8mmol l 1, the risk increased to 28%. In
women, the risks were much less, with the corresponding figures
being 4.1% and 8.7%. This disparity in risk has not previously been
documented in hypercalcaemia, although men in the United
Kingdom have a greater risk of cancer in general (NCIN, 2009). It
is important to note that malignancy was still uncommon, as most
cases of hypercalcaemia in this study were mild.
In men, 81% of the cancer associated with hypercalcaemia was
caused by lung, prostate, myeloma, colorectal and other haemato-
logical cancers. In hypercalcaemic men, clinicians should
consider the above malignancies, and investigate appropriately.
We did not study symptom reporting in our hypercalcaemic
participants, although it is likely that many of the patients
harbouring malignancy would have had additional diagnostic
pointers towards their diagnosis. In primary care, simple
investigations for all of these cancers (except for colorectal cancer)
are available, so initial cancer investigation may not require
specialist referral.
In women, cancer was much less common. This may reflect the
lower cancer incidence in general (2.4% vs 4.6%, in all participants in
this study); alternatively, primary hyperparathyroidism is much
more common in women, and is therefore likely to account for some
of the benign hypercalcaemia in this study (Mazeh et al, 2012).
CONCLUSIONS
Hypercalcaemia is known to be associated with cancer, but this
study shows that often it can predate the diagnosis of cancer in
primary care. It significantly increases the risk of cancer, especially
in men, and this effect is related to the degree of hypercalcaemia.
However, the overall risk of cancer is still small, especially with
minor elevations of calcium levels. Investigation strategies can be
designed to use these results, both at an individual level and in
developing guidelines for primary care in general.
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